Significant advances have been made in the development of vaccines against the most dangerous type of common cancer in women. 
The Cleveland Clinic in the United States has announced on October 26, 2021, that the triple-negative breast cancer vaccine will be tested on humans. 

breast cancer vaccine
Photo Credited to Cleveland Clinic 

Hormones or targeted drugs do not work against this type of breast cancer and mastectomy is the only way to prevent it. 

Vaccines for this dangerous type of breast cancer have been limited to laboratory and animal development. 

But the trial on humans is the most important development. 

The trial will include women who have survived triple-negative breast cancer at an early stage but are at high risk of recurrence. 

Researchers expect that the next step will be to include more healthy people at risk. 

“On a long-term basis, we expect it to be an effective vaccine that will help healthy women avoid this deadly type of breast cancer,” they said. 

They said that this is the type of breast cancer against which the treatment is the least effective. Triple-negative breast cancer affects 12 to 15 percent of women with this type of cancer, and about a quarter of patients die within 5 years of being diagnosed. 

The volunteers involved in the trial will be given the vaccine in 3 doses, which include a drug that will stimulate the immune system against a specific protein that increases this type of risk. 

Each dose will have an interval of 2 weeks and initially, a few women will be given a small amount of food followed by monitoring and then the quantity and number of women will be increased. 

The trial will include 18 to 24 women who have been diagnosed with early-stage cancer over the past three years. 

According to researchers, once we determine how many vaccines should be given, we will then examine its effects on the immune system, which will help determine how effective the vaccine is. 

The investigation is expected to be completed by September 2022 and will be funded by the US Department of Defense. 

The researchers said that the vaccine strategy could potentially work on other types of tumors as well and that if the trial was successful, it could help control cancer in adults.